Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation.
Adult
Aged
Chemoradiotherapy
Diffusion Magnetic Resonance Imaging
/ methods
Female
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Image Interpretation, Computer-Assisted
/ methods
Male
Middle Aged
Papillomavirus Infections
/ complications
Progression-Free Survival
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
04
02
2020
accepted:
23
05
2020
pubmed:
1
8
2020
medline:
29
12
2020
entrez:
1
8
2020
Statut:
ppublish
Résumé
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased in the period from the 1970s to 2004, due to increase of infection with human papilloma virus (HPV). This study aimed to examine the role of histogram analysis of the ADC in treatment response and survival prediction of patients with oropharyngeal squamous cell carcinoma and known human papillomavirus status. This was a retrospective single-center study. Following inclusion and exclusion criteria, data for 59 patients affected by T2-T4 (according to the 8th edition of the At univariable analysis, both human papillomavirus status and mean ADC were associated with progression-free survival (hazard ratio = 0.267, ADC and human papillomavirus status are related to progression-free survival in patients treated with chemoradiation for advanced oropharyngeal squamous cell carcinoma; however, this association seems to result from the strong association between ADC and human papillomavirus status.
Sections du résumé
BACKGROUND AND PURPOSE
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased in the period from the 1970s to 2004, due to increase of infection with human papilloma virus (HPV). This study aimed to examine the role of histogram analysis of the ADC in treatment response and survival prediction of patients with oropharyngeal squamous cell carcinoma and known human papillomavirus status.
MATERIALS AND METHODS
This was a retrospective single-center study. Following inclusion and exclusion criteria, data for 59 patients affected by T2-T4 (according to the 8th edition of the
RESULTS
At univariable analysis, both human papillomavirus status and mean ADC were associated with progression-free survival (hazard ratio = 0.267,
CONCLUSIONS
ADC and human papillomavirus status are related to progression-free survival in patients treated with chemoradiation for advanced oropharyngeal squamous cell carcinoma; however, this association seems to result from the strong association between ADC and human papillomavirus status.
Identifiants
pubmed: 32732272
pii: ajnr.A6695
doi: 10.3174/ajnr.A6695
pmc: PMC7658864
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1473-1479Informations de copyright
© 2020 by American Journal of Neuroradiology.
Références
J Radiat Res. 2011;52(4):522-30
pubmed: 21905311
J Clin Oncol. 2017 Dec 20;35(36):4057-4065
pubmed: 28777690
J Comput Assist Tomogr. 2012 Jan-Feb;36(1):131-7
pubmed: 22261783
Acta Oncol. 2015;54(9):1423-9
pubmed: 26264429
AJR Am J Roentgenol. 2013 Jan;200(1):35-43
pubmed: 23255739
Radiology. 2014 Aug;272(2):456-63
pubmed: 24749712
Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):670-671
pubmed: 30238903
Future Oncol. 2018 Oct;14(24):2521-2530
pubmed: 30265132
Cancer Imaging. 2016 Aug 19;16(1):23
pubmed: 27542718
Radiother Oncol. 2014 Mar;110(3):429-34
pubmed: 24630535
AJNR Am J Neuroradiol. 2017 Nov;38(11):2153-2160
pubmed: 28912282
ORL J Otorhinolaryngol Relat Spec. 2016;78(6):344-352
pubmed: 28245461
Clin Cancer Res. 2009 Feb 1;15(3):986-94
pubmed: 19188170
Clin Nucl Med. 2012 May;37(5):475-80
pubmed: 22475897
Eur Arch Otorhinolaryngol. 2014 May;271(5):1219-25
pubmed: 23880924
AJNR Am J Neuroradiol. 2018 Oct;39(10):1878-1883
pubmed: 30213805
Eur J Radiol. 2019 Apr;113:39-50
pubmed: 30927958
Radiology. 2013 Feb;266(2):531-8
pubmed: 23151830
Eur Radiol. 2016 Dec;26(12):4432-4441
pubmed: 26965504
Oncotarget. 2016 Nov 1;7(44):71761-71772
pubmed: 27708214
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Eur Radiol. 2016 Nov;26(11):4162-4172
pubmed: 26911889
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):339-45
pubmed: 20832179
AJNR Am J Neuroradiol. 2015 Apr;36(4):763-7
pubmed: 25721078
Curr Oncol Rep. 2019 Apr 17;21(6):52
pubmed: 30997577
Oral Oncol. 2018 Feb;77:9-15
pubmed: 29362130
Curr Treat Options Oncol. 2017 Jul;18(7):40
pubmed: 28555375
Radiol Med. 2017 May;122(5):345-352
pubmed: 28188603
Front Oncol. 2017 Jun 30;7:129
pubmed: 28713770
Eur J Radiol. 2015 Jan;84(1):108-116
pubmed: 25467228
Eur J Radiol. 2017 Jul;92:93-102
pubmed: 28624026
Sci Rep. 2018 Jan 24;8(1):1524
pubmed: 29367653